ArticleRSC advances2026
Exploring the changes in anticoagulant active ingredients before and after bovine bile fermentation of the traditional Chinese medicine Yaomu
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fermentation is a significant and specialized processing technology that primarily serves to enhance efficacy and reduce toxicity. Yaomu (YM) was fermented in a cellar using bovine bile as the fermentation matrix. However, the alterations in its active ingredients before and after processing remain poorly understood. An aggregation-induced emission fluorescence sensor (NITPA-S) was developed that employed S-2238 (S) to encapsulate the NITPA-Py-603 (NITPA) probe with the help of glutaraldehyde, creating an "ON" state. Thrombin hydrolyzed the sensor, releasing the probe in the "OFF" state, while thrombin inhibitors reversed this effect. We combined an HPLC fully automatic partial fraction collector and UHPLC-Q-TOF/MS for the separation, screening and identification of YM active compounds, which were used as indicators of anticoagulant activity to explore the changes in the content of YM before and after processing by using UHPLC-MS/MS and the sensor. A total of 211 compounds were collected and identified. Notably, karakoline, talatisamine, neoline, chasmanine and schaftoside exhibited the highest inhibition rates in YM. Furthermore, these compounds generally increased in concentration after processing (
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.